Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
NCT05504486 · Otsuka Pharmaceutical Development & Commercialization, Inc. · PHASE4 · withdrawn · last registry update 2023-01-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor strategic decision” | – | Registry record, Otsuka Pharmaceutical Development & Commercialization, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DRD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-13Phase 3 first posted: Ain Shams University, Haloperidol Injection (NCT06168773)
- 2023-11-18Results posted on the registry: InterveXion Therapeutics, LLC, IXT-m200 + Lorazepam (NCT04715230)
- 2023-11-18Also stopped (terminated): InterveXion Therapeutics, LLC, IXT-m200 + Lorazepam (NCT04715230)
- 2023-08-18Results posted on the registry: Ferring Pharmaceuticals, Quinagolide 360 µg + Quinagolide 720 µg (NCT03692403)
- 2023-08-01Phase 3 first posted: Wake Forest University Health Sciences, Magnesium Sulfate + Metoclopramide 10mg (NCT05967442)
- 2023-06-09Phase 3 first posted: Christian Hassager, Dexamethasone + Olanzapine (NCT05895838)
- 2023-05-12Phase 3 first posted: Proton Collaborative Group, a drug against DRD2 (NCT05856773)
- 2023-04-07Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., Olanzapine + Haloperidol (NCT05803642)
- 2023-01-19Phase 3 first posted: Alexandria University, Quatiapine + Haloperidol (NCT05690698)
- 2022-12-14Results posted on the registry: Adrianna Vlachos, MD, Trifluoperazine (NCT03966053)
- 2022-12-14Also stopped (terminated): Adrianna Vlachos, MD, Trifluoperazine (NCT03966053)
- 2022-11-04Also stopped (terminated): The University of Hong Kong, Olanzapine + Haloperidol (NCT02380118)
- 2022-11-04Also stopped (terminated): The University of Hong Kong, Olanzapine oro-dispersible 5Mg Tab + Haloperidol 2Mg encapsulated Tab (NCT03246620)
- 2022-11-01Results posted on the registry: Supernus Pharmaceuticals, Inc., SPN-810 (18 mg) + SPN-810 (36 mg) (NCT02618408)
- 2022-10-19Phase 3 first posted: Oman Medical Speciality Board, Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg) (NCT05586763)
- 2022-09-07Results posted on the registry: Ferring Pharmaceuticals, Quinagolide 1080 µg + Placebo (NCT03749109)
- 2022-09-01Results posted on the registry: M.D. Anderson Cancer Center, Chlorpromazine + Haloperidol (NCT03021486)
- 2022-07-14Also stopped (terminated): Wake Forest University Health Sciences, 0.5% bupivacaine + Standard Care (NCT01785459)
- 2022-06-24Phase 3 first posted: M.D. Anderson Cancer Center, Haloperidol + Chlorpromazine (NCT05431595)
- 2022-06-14Results posted on the registry: Joseph Dib, Haloperidol + Promethazine + Chlorpromazine + Haloperidol + Promethazine (NCT03639558)
- 2022-06-08Results posted on the registry: Cycle Pharmaceuticals Ltd., Haloperidol Tablets, Mylan Pharmaceuticals Inc. + Haloperidol Tablets, Cycle Pharmaceuticals Ltd (NCT04411940)
- 2022-06-08Results posted on the registry: Cycle Pharmaceuticals Ltd., Haloperidol Tablets, Mylan Pharmaceuticals Inc. + Haloperidol Tablets, Cycle Pharmaceuticals Ltd (NCT04411953)
- 2022-05-11Also stopped (terminated): Erasmus Medical Center, Haloperidol + Placebo (NCT03628391)
- 2022-02-28Phase 3 first posted: Negovsky Reanimatology Research Institute, Sevoflurane + Propofol (NCT05259631)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision